30/01/2025
RNAssist is revolutionising vaccine distribution 🌍💉⬇️
The COVID-19 pandemic highlighted the need for better global vaccine access, especially in remote regions where ultra-cold storage is practically impossible.
RNAssist has developed an innovative solution with its TheraPHIX™ RNA stabiliser - a thermostable formulation that enables RNA vaccines to be stored at ambient temperatures.
Using a deep eutectic solvent (DES), TheraPHIX™ protects RNA within lipid nanoparticles, maintaining vaccine stability and potency without the need for freezing.
With CPI’s support, and funding from Innovate UK, RNAssist has:
🔬 Optimised RNA vaccine stabilisation with Deep Eutectic Solvents (DES).
⚙️ Scaled up production and demonstrated large-scale manufacturability.
🌡️ Achieved stability at 37°C for months, with higher potency than controls.
TheraPHIX™ is set to transform global vaccine equity, delivering life-saving vaccines to underserved communities.
Learn more here ➡️ https://www.uk-cpi.com/case-studies
| |
| |